Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 886 to 900 of 1423 results for primary care

  1. Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

    Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.

  2. Urethrotech UCD for difficult or failed catheterisation (MIB116)

    NICE has developed a medtech innovation briefing (MIB) on the Urethrotech UCD for difficult or failed catheterisation .

  3. What impact does brief advice to promote physical activity have on mental wellbeing?

    Comes from guidance Physical activity: brief advice for adults in primary care Number PH44 Date issued May 2013 Other details

  4. Medicines associated with dependence or withdrawal symptoms. Patient decision aid full version on should I stop my benzodiazepine or z-drug?

    personalised care for adults prescribed medicines associated with dependence or withdrawal symptoms: Framework for action for integrated...

  5. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.

  6. Repetitive short-pulse transscleral cyclophotocoagulation for glaucoma (HTG576)

    Evidence-based recommendations on short-pulse transscleral cyclophotocoagulation for glaucoma. This involves using repeated short pulses of laser energy to destroy some of the cells in the eye that produce fluid.

  7. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.

  8. Virtual ward platform technologies for acute respiratory infections: early value assessment (HTG697)

    Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections.

  9. Sorafenib for treating advanced hepatocellular carcinoma (TA474)

    Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

  10. PROPATEN heparin-bonded vascular graft for peripheral arterial disease (MIB42)

    NICE has developed a medtech innovation briefing (MIB) on the PROPATEN heparin-bonded vascular graft for peripheral arterial disease

  11. How does the duration and frequency of brief advice influence its effectiveness and cost effectiveness? For example, do 'micro interventions' of less than 1–2 minutes have an impact on physical activity?

    Comes from guidance Physical activity: brief advice for adults in primary care Number PH44 Date issued May 2013 Other details

  12. How can brief advice be tailored to have the greatest impact on specific groups? For example, can it be tailored to meet the needs of people of a particular gender, socioeconomic status or with a particular disability?

    Comes from guidance Physical activity: brief advice for adults in primary care Number PH44 Date issued May 2013 Other details

  13. VAAFT for treating anal fistulae (MIB102)

    NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .

  14. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)

    NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .

  15. The Epidrum for aiding access to the epidural space (MIB23)

    NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space